A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases - 16/09/17

Doi : 10.1016/j.biopha.2017.07.084

Reza Shafiee-Nick ^a,^b, Amir R. Afshari ^a,^b, Seyed Hadi Mousavi ^c, Abbasali Rafighdoust ^d, Vahid Reza Askari ^b, Hamid Mollazadeh ^e, Sahar Fanoudi ^b, Elmira Mohtashami ^f, Vafa Baradaran Rahimi ^b, Moein Mohebbi ^g, Mohammad Mahdi Vahedi ^b,^h,^⁎
^a Pharmacological Research Center of Medicinal Plants, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
^b Department of Pharmacology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
^c Medical Toxicology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
^d Department of Cardiology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
^e Department of Physiology and Pharmacology, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
^f Department of Pharmacodynamic and Toxicology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
^g Department of Internal Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
^h Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

^⁎Corresponding author at: Department of Pharmacology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.Department of PharmacologySchool of MedicineMashhad University of Medical SciencesMashhadIran

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	16
Iconographies	3
Vidéos	0
Autres	0

Abstract

Phosphodiesterases are a group of enzymes that hydrolyze cyclic nucleotides, which assume a key role in directing intracellular levels of the second messengers' cAMP and cGMP, and consequently cell function. The disclosure of 11 isoenzyme families and our expanded knowledge of their functions at the cell and molecular level stimulate the improvement of isoenzyme selective inhibitors for the treatment of various diseases, particularly cardiovascular diseases. Hence, future and new mechanistic investigations and carefully designed clinical trials could help reap additional benefits of natural/synthetic PDE inhibitors for cardiovascular disease in patients. This review has concentrated on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.

Le texte complet de cet article est disponible en PDF.

Keywords : Phosphodiesterase, Cardiovascular disease, Potential therapeutic, Phosphodiesterase inhibitors

Plan

Cardio-protection effects

PDE10

PDE11

Natural PDE inhibitors

Concluding remarks

Conflict of interests

Export

Vol 94

P. 541-556 - octobre 2017 Retour au numéro

Article précédent

Colon cancer associated transcripts in human cancers
Yincong Chen, Haibiao Xie, Qunjun Gao, Hengji Zhan, Huizhong Xiao, Yifan Zou, Fuyou Zhang, Yuchen Liu, Jianfa Li

| Article suivant

Thrombotic and cardiovascular risks in type two diabetes; Role of platelet hyperactivity
Almottesembellah Gaiz, Sapha Mosawy, Natalie Colson, Indu Singh

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases - 16/09/17

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL